Loading
Thyroid Cancer Diagnosis and Treatment / Thyroid Disorders and Treatments · Journal article
Frontiers in Endocrinology · September 8, 2026
Well-designed and adequately powered for the question it asks.
This nationwide retrospective cohort study demonstrates that thyroidectomy and subsequent thyroid hormone therapy are associated with significantly increased odds of developing multiple metabolic abnormalities (obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome, and MASLD) within 5–10 years in thyroid cancer survivors compared to matched general population controls and untreated thyroid cancer patients. The findings support metabolic surveillance in this population but do not yet establish whether modified hormone management can reduce these risks.
Retrospective, population-based cohort study. Thyroid cancer patients and matched individuals from the general population without thyroid cancer, enrolled from the Korea National Health Insurance Service national registry.. Intervention: Thyroidectomy and thyroid hormone therapy in thyroid cancer survivors. Compared with: Matched general population without thyroid cancer; thyroid cancer patients without thyroidectomy; thyroidectomy patients stratified by thyroid hormone therapy status. South Korea (nationwide cohort from Korea National Health Insurance Service).
Thyroidectomy associated with higher odds of multiple metabolic abnormalities compared with matched general population without thyroid cancer, with most associations evident from 5 years onward and some from 8 years Among thyroid cancer patients who underwent thyroidectomy, thyroid hormone therapy was significantly associated with metabolic abnormalities In sex-stratified analyses, overall patterns were largely similar; however, MASLD was not significantly associated with thyroidectomy or thyroid hormone therapy in males
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians managing thyroid cancer survivors should incorporate metabolic monitoring into long-term follow-up protocols, particularly screening for obesity, diabetes, hypertension, dyslipidemia, and metabolic syndrome. These findings suggest the need for individualized thyroid hormone dosing strategies and metabolic risk assessment, though interventional studies are needed to determine whether such modifications reduce long-term metabolic burden.
Rigorous nationwide population-based cohort study with large sample, long follow-up, and multivariable adjustment demonstrates clear associations between thyroidectomy/thyroid hormone therapy and multiple metabolic outcomes; not practice-changing because it establishes risk rather than testing an intervention to mitigate it.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing thyroid cancer survivors should incorporate metabolic monitoring into long-term follow-up protocols, particularly screening for obesity, diabetes, hypertension, dyslipidemia, and metabolic syndrome. These findings suggest the need for individualized thyroid hormone dosing strategies and metabolic risk assessment, though interventional studies are needed to determine whether such modifications reduce long-term metabolic burden.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background As long-term survival rates improve among thyroid cancer patients, the metabolic consequences of thyroidectomy and thyroid hormone therapy have gained increasing importance. While these treatments are crucial for cancer management, their long-term effects on metabolic health remain inadequately understood. Methods We conducted a retrospective, population-based cohort study utilizing nationwide data from the Korea National Health Insurance Service. We estimated the risk of incident metabolic abnormalities (i) among patients with TC who underwent thyroidectomy compared with matched individuals from the general population without TC, (ii) among TC patients according to thyroidectomy status, and (iii) among TC patients who underwent thyroidectomy, according to thyroid hormone therapy status. The incidence of obesity, diabetes mellitus, hypertension, dyslipidemia, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease (MASLD) within 5, 8, and 10 years was estimated using multivariable logistic regression models, adjusting for age, sex, household income, alcohol consumption, smoking status, and physical activity. Results Thyroidectomy was associated with higher odds of multiple metabolic abnormalities compared with the matched general population without TC and to TC patients without thyroidectomy, with most associations evident from 5 years onward and some from 8 years. Among TC patients who underwent thyroidectomy, thyroid hormone therapy was significantly associated with metabolic abnormalities. In sex-stratified analyses, overall patterns were largely similar; however, MASLD was not significantly associated with thyroidectomy or thyroid hormone therapy in males. Conclusion Thyroidectomy and thyroid hormone therapy are associated with incidence of metabolic abnormalities within 5, 8, or 10 years among thyroid cancer survivors. These findings support ongoing metabolic monitoring in thyroid cancer survivors and warrant further studies to determine whether individualized hormone management can reduce long-term metabolic risk.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.